Ankit Mahadevia - 01 Feb 2023 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
CEO and President, Director
Signature
/s/ Tamara Joseph, Attorney-in-Fact for Ankit Mahadevia
Issuer symbol
SPRO
Transactions as of
01 Feb 2023
Net transactions value
$0
Form type
4
Filing time
03 Feb 2023, 18:38:32 UTC
Previous filing
03 Feb 2022
Next filing
06 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +531,914 +191% $0.000000 810,118 01 Feb 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
F2 Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 691,205 RSUs held by the Reporting Person.